TITLE

El gal�n caribe�o

PUB. DATE
February 2008
SOURCE
Vistazo;2/1/2008, Issue 971, p66
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
30071529

 

Related Articles

  • Brief reviews of books. Muhly, J.D. // Journal of the American Oriental Society;Jan-Mar97, Vol. 117 Issue 1, p211 

    Reviews the book `Gebel El-Zeit, 1: Les Mines de galne,' written by Georges Castel.

  • Galán de Noche. Cassells, Cyrus // More Than Peace & Cypresses;1/ 1/2004, p69 

    The poem "Galán de Noche," by Cyrus Cassells is presented. First Line: Our days in the grace of the Alhambra; Last Line: adiós, galán de noche.

  • Biochemical and structural analysis of missense mutations in N -acetylgalactosamine-6-sulfate sulfatase causing mucopolysaccharidosis IVA phenotypes. Sukegawa, Kazuko // Human Molecular Genetics;May2000, Vol. 9 Issue 9 

    Studies missense mutations in the N-acetylgalactosamine-6-sulfate-sulfatase (GALNS) gene from mucopolysaccharidosis IVA (MPS IVA) patients. Biochemical and structural analysis of the mutations; Characterization; Precursor forms of the mutant proteins; Structural model of human GALNS; Reasons...

  • Deceuninck distribution gets a boost.  // Glass Age;Oct2005, Vol. 48 Issue 10, p14 

    Reports that Deceuninck Group has opened its additional distribution center in Galne in Wiltshire, England on September 1, 2005. Investments on the warehouse; Number of employees.

  • Effect of indirect minima carrier population on the output characteristics of AlGalnP... Patel, D.; Pikal, J.M.; Menoni, C.S.; Thomas, K.J.; Kish, F.A.; Hueschen, M.R. // Applied Physics Letters;11/15/1999, Vol. 75 Issue 20, p3201 

    Studies the effect of indirect minima carrier population on the output characteristics of AlGalnP semiconductor light-emitting diodes. Influence of carrier transfer to the indirect X level on the efficiency of AlGalnP light-emitting diodes; Measured electroluminescence spectra of AlGalnP...

  • Uso de vectores derivados de virus adenoasociados para el tratamiento de la enfermedad de Morquio A. ALMÉCIGA-DÍAZ, CARLOS JAVIER; RUEDA-PÁRAMO, MARÍA ANDREA; ECHEVERRI, OLGA YANETH; MONTA˜O, ADRIANA MARÍA; TOMATSU, SHUNJI; BARRERA, LUIS ALEJANDRO // Universitas Médica;jul-sep2009, Vol. 50 Issue 3, p356 

    Toward the development of a gene therapy strategy for the mucopolysaccharidosis IV A (MPS IV A, Morquio A ), in this work we evaluated the capability of an AAV vector to express the N-acetilgalactosamine- 6-sulfate sulfatase (GALNS) gene in HEK293 cells, human mucopolysaccharidosis IV A...

  • The Effect of D-Galactosamine on Lean and Steatotic Rat Hepatocytes in Primary Culture. KUČERA, O.; LOTKOVÁ, H.; SOBOTKA, O.; ČERVINKOVÁ, Z. // Physiological Research;2015 Supplement 5, Vol. 64, pS637 

    The aim of our work was to compare the effect of D-galactosamine (GalN) on primary cultures of lean and steatotic rat hepatocytes isolated from intact and fatty liver, respectively. GalN caused more severe injury to steatotic hepatocytes than to lean cells as documented by lactate dehydrogenase...

  • Enzyme Replacement in a Human Model of Mucopolysaccharidosis IVA In Vitro and Its Biodistribution in the Cartilage of Wild Type Mice. Dvorak-Ewell, Melita; Wendt, Dan; Hague, Chuck; Christianson, Terri; Koppaka, Vish; Crippen, Danielle; Kakkis, Emil; Vellard, Michel // PLoS ONE;2010, Vol. 5 Issue 8, p1 

    Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by deficiency of Nacetylgalactosamine- 6-sulfatase (GALNS), an enzyme that degrades keratan sulfate (KS). Currently no therapy for MPS IVA is available. We produced recombinant human (rh)GALNS as a...

  • Enzyme replacement therapy for Morquio A: an active recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in Escherichia coli BL21. Rodríguez, Alexander; Espejo, Ángela J.; Hernández, Alejandra; Velásquez, Olga L.; Lizaraso, Lina M.; Cordoba, Henry A.; Sánchez, Oscar F.; Alméciga-Díaz, Carlos J.; Barrera, Luis A. // Journal of Industrial Microbiology & Biotechnology;Nov2010, Vol. 37 Issue 11, p1193 

    Mucopolysaccharidosis IVA (MPS IVA) is an autosomal recessive disorder caused by N-acetylgalactosamine-6-sulfate sulfatase (GALNS) deficiency. Currently no effective therapies exist for MPS IVA. In this work, production of a recombinant GALNS enzyme (rGALNS) in Escherichia coli BL21 strain was...

  • Structural and functional analysis of N-acetylgalactosamine-6-sulfate sulfatase using bioinformatics tools: Insight into Mucopolysaccharidosis IVA. Sudhakar, Sarath Chandar; Mahalingam, Kulandaivelu // Journal of Pharmacy Research;Nov2011, Vol. 4 Issue 11, p3958 

    Mucopolysaccharidosis IVA (MPS IVA) is caused by mutations in N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene. Genotype phenotype correlations of MPS IVA remain unclear due to lack of structural data of GALNS variants. In this structural-functional study, the impact of mutations on GALNS...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics